Search

Your search keyword '"Jutel, M."' showing total 669 results

Search Constraints

Start Over You searched for: Author "Jutel, M." Remove constraint Author: "Jutel, M."
669 results on '"Jutel, M."'

Search Results

1. Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study

2. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app

3. Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study

4. One‐strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable.

5. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

7. Real-World Adherence and Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced Allergic Rhinitis and Asthma

8. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

10. From MASK-air® and SILAM to CATALYSE (Climate Action to Advance HeaLthY Societies in Europe)

13. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

14. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

15. Rhinitis associated with asthma is distinct from rhinitis alone:The ARIA-MeDALL hypothesis

16. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

18. The ARIA-MeDALL hypothesis

19. Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

21. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products

23. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

24. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

25. AllergoOncology: Danger signals in Allergology and Oncology. A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper

26. AllergoOncology: Danger signals in Allergology and Oncology. A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper

27. Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app.

28. Climate change and global health: A call to more research and more action

30. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

32. Anwendung von Biologika bei allergischen und Typ-2- entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI

33. Development and validation of combined symptom-medication scores for allergic rhinitis*

34. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model

35. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air® real-world data

36. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

37. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

38. Neuroprotective Natural Antibodies to Assemblies of Amyloidogenic Peptides Decrease with Normal Aging and Advancing Alzheimer's Disease

39. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

40. Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

41. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

42. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

43. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

44. Aligning the good practice mask with the objectives of the European innovation partnership on active and healthy ageing

47. Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic – An EAACI Position Paper

48. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19

49. Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper

50. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

Catalog

Books, media, physical & digital resources